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Abstract 
This study investigates the effect of well–defined poly(dimethylsiloxane)–poly(ethylene glycol) ABA 
linear block co-oligomers on the proliferation of human dermal fibroblasts. The co-oligomers assessed 
ranged in molecular weight (MW) from 1335 to 5208 Da and hydrophilic–lipophilic balance (HLB) 
from 5.9 to 16.6 by varying the number of both PDMS and PEG units. In general, it was found that 
co-oligomers of low MW or intermediate hydrophilicity significantly reduced fibroblast proliferation. 
A linear relationship between down-regulation of fibroblast proliferation and the ratio HLB/MW was 
observed at concentrations of 0.1 and 1.0 wt % of the oligomers. This enabled the structures with 
highest efficiency to be determined.  These results suggest the possible use of the PEG–PDMS–PEG 
block co-oligomers as an alternative to silicone gels for hypertrophic scar remediation. 
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1. Introduction 
Poly(dimethyl siloxane) and poly(ethylene glycol) (PEG) are two of the most used polymeric 
biomaterials, dating back to the middle of last century.1 Both polymers are well-tolerated by the body 
and have widespread application in drug delivery, medical devices and cell culture ware.2-4 However, 
adverse effects of these well-known polymers, albeit uncommon, have occurred. These include 
immune system response to PEG,5 cytotoxic reaction to silicone oil6  and fibrotic capsule formation 
associated with silicone elastomer implants.7 Poly(dimethyl siloxane) (PDMS) silicones are 
exceptionally hydrophobic but when modified with hydrophilic PEG, amphiphilic non-ionic 
surfactant structures are formed that are dispersible in water as micelles and vesicles and which have 
important cosmetic and industrial uses,8 as well as potential drug delivery applications.9  
Despite the fact that copolymers of PEG and PDMS are certified for topical application,10-11 we have 
recently reported that certain rake-type PDMS-PEG copolymers affect both dermal fibroblasts and 
keratinocytes in vitro by reducing proliferation, viability and fibroblast collagen synthesis.12 The 
effect is strongly related to molecular weight (MW): from a study of the different copolymer fractions 
separated by preparative size exclusion chromatography, it was found that the lower MW fractions 
had the greatest impact on both cell types. This observation that non-ionic amphiphilic copolymers 
can have adverse effects on cells is not unique to PDMS-PEG copolymers. For example, 
polycaprolactone–PEG exhibited toxicity towards cells derived from human colon adenocarcinoma,13 
while copolymers of polyethylene oxide and polypropylene oxide (Pluronics), used as protecting 
agents in suspension cultures of mammalian cells, have been shown to interact with the cell plasma 
membrane and affect cell phenotype.14  
The interaction of amphiphilic polymers with fibroblasts may have therapeutic value. For instance, we 
have found that silicone gel sheets (SGS), commonly worn over hypertrophic and keloid scars to 
reduce erythema, release minute amounts of hydroxyl-functionalized low MW silicone oils which 
may play a role in the mechanism of action.15 Such an observation is significant, since it had been 
widely regarded that the mechanism of action of SGS was through the regulation of the hydration of 
scar tissue, i.e. they are a passive not an active therapy.16 This was based on the data showing that low 
MW hydroxyl-terminated linear oligomers are able to diffuse through the stratum corneum17 at a rate 
similar to small hydrophobic molecules of 2.5 x 10-9 cm2s-1.18 These studies, along with examination 
of the rake co-polymers,12 suggest the PDMS–PEGs have potential as a scar therapy and may provide 
a substitute for SGS or an alternative to other therapies commonly used, such as injections of 
antiproliferative agents 5-FU19 or bleomycin,20 treatment with specific cytokines, extra cellular matrix 
modulators, or growth factors.21 
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In this study, we have investigated whether well–defined ABA PDMS–PEG block co-oligomers can 
emulate the effects of the low MW rake copolymers previously studied.12 A series of co-oligomers 
varying in number of repeating PDMS and PEG units were synthesized and placed on human dermal 
fibroblasts to examine the correlation between the structure and properties of the oligomers and 
fibroblast proliferation.  
2. Methods 
2.1. PDMS–PEG oligomers 
PDMS-PEG oligomers were prepared by separately synthesizing discrete allyl PEGs and α,ω-
dihydro(polydimethylsiloxane)s then coupling these via a hydrosilylation reaction similar to Markovic 
et al..22 This generated a small library of oligomers which are summarized in Table 1. Complete 
details of the synthesis can be found in the supporting information. 
2.2  Characterization 
The synthesized oligomers were characterized using nuclear magnetic resonance (NMR) where 
spectra were obtained on a Bruker Avance 400MHz spectrometer (1H 400MHz, 13C 100 MHz). The 
hydrophilic lipophilic balance (HLB) factor for each oligomer was calculated using Equation 1,23  
HLB = 20 x (MH / (MH + ML))  (1) 
where MH is the MW of the hydrophilic PEG, and ML is the MW of the lipophilic PDMS. Critical 
aggregation concentrations were determined using surface tension measurements using the methods 
described previously.24 Briefly, a Krüss model DVT-10 drop volume tensiometer equipped with a 
syringe pump was used to drive the oligomer solution through a capillary into a continuous phase; the 
time recorded commenced from when the first drop was detected from the capillary and the time 
elapsed between subsequent droplets formed was recorded. At a constant flow rate, the volume of the 
droplet, related to both the flow rate and time taken for droplet formation, is directly proportional to 
the interfacial tension between the two phases. 
2.3 Dermal Fibroblasts 
2.3.1 Isolation and culture 
Primary human dermal fibroblasts were isolated from consenting patients undergoing elective 
abdominal or breast reduction surgery. Ethics approval was obtained from the Queensland University 
of Technology’s Review Board (3673H) and associated hospitals, along with written informed 
consent from patients prior to them undergoing surgery. In addition, the studies were conducted in 
strict accordance to the Declaration of Helsinki Principles.  
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Dermal skin sections were comminuted and digested in a 0.05 % collagenase solution (Gibco) 
overnight at 37 °C. Following digestion, the suspension was centrifuged at 400 g for 10 min before 
removing the supernatant and resuspending the resulting cell pellet prior to transfer into a tissue 
culture flask. Fibroblasts were cultured in high glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM, Invitrogen) supplemented with fetal calf serum (10 %, FCS, Hyclone), penicillin, 
streptomycin and L–glutamine (all Invitrogen). Fibroblasts were maintained in a humidified 
atmosphere (5 % CO2) at 37 °C with the culture medium being refreshed every 3–5 days. Fibroblasts 
utilized in experimental assays were used at low passage number (p4–9). 
2.3.2 Fibroblast Proliferation 
Prior to exposing the fibroblasts to the siloxane oligomers, solubility of 1% oligomer solutions in 
culture medium were assessed for three days at either room temperature or 37 °C. One of the 
oligomers, PEG8–PDMS15.2–PEG8, was insoluble and excluded from fibroblast proliferation 
experiments. 
To examine fibroblast proliferation, test oligomer solutions were prepared in cell culture medium at 
concentrations of 1, 0.1, 0.01 and 0.001 % wt/v. Fibroblasts were seeded into 96 well plates (3 x 
103cells / well) and incubated for 24 h to allow cell adhesion to the well surface. Following 
incubation, the culture medium was aspirated and replaced with the required amount of the test 
solution. Experimental controls included exposing the fibroblasts to only cell culture medium. 
Fibroblasts exposed to the test and control solutions were then incubated for a further 48 hours.  
Fibroblast proliferation was determined using a CyQUANT cell proliferation assay kit (Invitrogen). 
On completion of the proliferation assay, cells were washed with PBS and stored at -80 °C until 
analysis. For analysis, the well plates were allowed to reach RT before the CyQUANT reagent was 
added and the fluorescence measured at 480ex / 520em nm. The results have been expressed as the 
number of cells remaining following exposure to the test solutions as a ratio of the number of cells 
remaining after exposure to the control solution. In addition to assessing fibroblast proliferation, 
representative images of fibroblasts exposed to the oligomers were taken in 24 well plates at a cell 
seeding density of 2 x 104cells / well. Following exposure to the oligomer and control solutions, 
representative images observing fibroblast morphology were acquired at 10x magnification.  
2.3 Statistics 
Fibroblast proliferation assays were performed three times; each variable, oligomer and concentration, 
were tested in triplicate in each of the replicate experiments. Proliferation data are presented as a 
mean (normalized) ± standard error of the mean. The fibroblast proliferation data was assessed by the 
students t-test with a p <0.05 considered as significant.  
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3 Results 
3.1 Synthesis of PDMS–PEG oligomers  
Our previous study identified a commercially available polydisperse PDMS–PEG rake copolymer 
capable of reducing proliferation of dermal fibroblasts in vitro.12 Subsequent assay-guided 
fractionation of this copolymer mixture using size exclusion chromatography revealed that the activity 
was attributable to a low MW component with an average structure consisting of 7 dimethyl siloxane 
backbone units with 2 of these units having methoxy PEG 350 as pendant groups (Fig. 1A).25 To 
investigate if the same effect on fibroblast proliferation observed previously with the mixed rake 
copolymers could be emulated by well–defined ABA block PDMS–PEG co–oligomers (Fig. 1B) we 
synthesized a homologous series of these ABA structures. Generation of this small library was a result 
of coupling four different allyl–PEGs and two di-hydride terminated PDMS of different MW via a 
hydrosilylation reaction (Scheme 1). All resulting co-oligomers were either water soluble or water 
dispersible except for one, the PEG8–PDMS15.2–PEG8, which was completely insoluble and not used 
further for this study.  
Synthesis of the discrete PEGs containing reactive allyl termini was based on the methodology first 
reported by Keegstra et al.26 and Delamarche et al.27 The polydisperse allyl PEGs were prepared by 
allylation of the corresponding commercially available mono methyl ethers. Hydrophobic α,ω–
dihydro(polydimethylsiloxane) core blocks were prepared by traditional trifluoromethansulfonic acid 
catalyzed ring-opening equilibration polymerization of octamethylcyclotetrasiloxane (D4)28 using 
tetramethyldisiloxane to generate hydrosiloxane end-group functionality.29 Coupling of the 
hydrosiloxane-terminated siloxanes with the allyl PEGs using a hydrosilylation reaction (Scheme 1) 
generated a series of ABA block oligomers we have referred to as PEGm–PDMSn–PEGm with n being 
the PDMS repeat unit length and m the PEG length. Note that for consistency the subscripts used in 
the oligomer ID reflect the values for n and m in Scheme 1 and do not include the groups between the 
PEG and PDMS repeat units. The generalized structure of the synthesized oligomers is shown in 
Figure 1B. Note that considering the low MW of these PEG–PDMS–PEGs, we have referred to them 
as oligomers and not polymers, although for simplicity the nomenclature used for the siloxane units is 
poly(dimethyl siloxane) (PDMS). Likewise, the tetra- and octa- ethylene glycols have been referred to 
as PEGs.  
The critical aggregation concentration (CAC) was determined using surface tension measurements 
across a range of concentrations (graphically shown in Figure 2 and summarized in Table 1). 
Oligomers of higher hydrophobic content made from either PEG4 or PEG8 have limited solubility in 
water and therefore their CACs were not able to be determined. The MW and hydrophilic lipophilic 
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balance (HLB) were determined using NMR spectroscopy and Equation 1, respectively, and are 
summarized in Table 1. 
 
3.2 Examination of PDMS-PEG molecular weight and HLB on dermal fibroblast 
proliferation  
The effect of PEG-PDMS-PEG on dermal fibroblast proliferation was examined by exposing isolated 
human dermal fibroblasts within their growth phase to the library of synthesized PDMS-PEGs. The 
degree of proliferation was determined and normalized to the control fibroblasts exposed to culture 
medium without any added PDMS-PEGs.  Representative images showing morphology of the 
fibroblasts exposed to the oligomers are shown in Fig. 3 (1% wt/v exposure concentration). Exposure 
to 
PEG4–PDMS10.5–PEG4 (Fig. 3B) clearly shows disruption to fibroblast morphology. Cells appear to 
have lost their fibroblastic appearance, with signs of rounding and jagged edges along the cell 
membranes. Visualization of the cells exposed to PEG16–PDMS10.5–PEG16 was not possible due to the 
fine dispersion of the oligomer that completely obscured the image (Fig. 3E1). In this case, the test 
medium was removed following exposure, and the cells were gently washed with PBS to remove 
residual oligomer before adding fresh medium prior to immediate image capture. The image of the 
cells with the oligomer removed (Fig 3E2) revealed similar changes to morphology as shown with 
PEG4–PDMS10.5–PEG4. Exposure of the cells to the remaining oligomers  (Fig 3A, C, D, F, and G) 
had little or no affect on morphology relative to the control (Fig. 3H). 
The images also reveal the solution properties of the oligomers within the cell culture media. Images 
of fibroblasts exposed to the two oligomers containing the highest lipophilic components (shortest 
PEG blocks), namely, PEG4–PDMS10.5–PEG4 (Fig. 3A) and PEG4–PDMS15.2–PEG4 (Fig. 3B), appear 
to be blurred. This is due to out-of-focus phase-separated droplets of the oligomers present closer 
towards the surface of the tissue culture well. A similar phenomenon between PEG8–PDMS10.5–PEG8 
(Fig. 3C) and culture medium was also evident, though in this case large vesicles were formed. 
The degree of proliferation, relative to the control, after exposure to each oligomer from 0.001 - 1 % 
wt/v is summarized in Table 2. This concentration range was used to compare the library of  
PDMS–PEGs and possible dose effects on fibroblast proliferation. For the oligomers with the longest 
PEG blocks, namely PEG44–PDMS10.5–PEG44 and PEG44–PDMS15.2–PEG44, there was no decrease in 
proliferation relative to the control within the concentration range examined. Treatment with each of 
the other oligomers at 1 % wt/v resulted in a significant reduction in cell proliferation. Exposure to 
PEG4–PDMS10.5–PEG4 (1 % wt/v) and PEG16–PDMS10.5–PEG16 (1 and 0.1 % wt/v) resulted in the 
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most pronounced decrease in fibroblast proliferation, while exposure to  
PEG8–PDMS10.5–PEG8 across the concentration range resulted in a significant decrease in fibroblast 
proliferation. These results are also reflected in the reduced cell numbers observed in Figs. 3B, C and 
E2. 
The effect on fibroblast proliferation was plotted against MW of the oligomers (Fig. 4). The highest 
oligomer concentration examined (1 % wt/v), with the exception of PEG4–PDMS15.2–PEG4, showed a 
trend where treatment of the cells with the lower MW oligomers led to a decrease in fibroblast 
proliferation. The highest reduction in fibroblast proliferation was found when the cells were exposed 
to the lowest MW oligomer, PEG4–PDMS10.5-PEG4. In this case, the proliferation was reduced by 
90%. Conversely, the two highest MW oligomers, PEG44–PDMS10.5–PEG44 and 
PEG44–PDMS15.2–PEG44 (MW > 4500Da), reduced fibroblast proliferation by less than 10% at the 
highest concentration and had no significant effect on proliferation over the concentration range 
examined. 
In addition to a change in oligomer MW, altering the number of PDMS and PEG repeating units 
changes the hydrophilic and lipophilic balance of the oligomers (Table 1). In Fig. 5, the same 
fibroblast proliferation data is presented as a function of oligomer HLB at each concentration. The 
oligomers examined ranged from a HLB of 5.9 to 16.6. For each of the oligomer concentrations 
examined (1, 0.1, 0.01 and 0.001 % wt/v), a trend was observed whereby fibroblast proliferation was 
reduced when exposed to oligomers for the intermediate HLB values (7.5 to 13.0). 
As well as examining the change in oligomer MW or HLB independently and the resulting impact on 
fibroblast proliferation, the two parameters were combined as the single variable, 100HLB/MW. 
Fibroblast proliferation as a function of 100HLB/MW is shown in Fig. 6 at oligomer exposure 
concentrations of 1 and 0.1 %wt/v. Data concerning 0.01 and 0.001 % wt/v were excluded as it was 
previously shown, with the exception of PEG8–PDMS10.5-PEG8, that proliferation at these exposure 
concentrations were not significantly different compared to the control. The results reveal a trend 
indicating that as the ratio of 100HLB/MW for the oligomers increased there was a higher reduction 
in cell proliferation. 
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4 Discussion 
The motivation behind the present research was based on our previous findings12 which  demonstrated 
that exposure to PDMS-PEG rake copolymers reduced cell viability and proliferation. Results 
suggested the effect on cell viability and proliferation was related to the MW of the copolymer. To 
further investigate these observations, we have synthesized a small library of ABA PEG–PDMS–PEG 
linear block copolymers to study the structure–property relationship between the synthesized 
oligomers and fibroblast proliferation. 
The library of ABA PEG–PDMS–PEG oligomers was prepared using combinations of discrete allyl-
PEG with 4 and 8 repeating units or non–discrete allyl-PEG of 16 or 44 units (on average), and 
dihydro-terminated PDMS of 10.5 or 15.2 units. The rationale behind using discrete PEGs at the low 
MW range was to avoid overlap in the MW distribution, which may hinder recognition of structure-
property relationships. Similarly, for the longer PEG materials, non–discrete materials were used, as 
the likelihood of MW overlap was minimal. The siloxane block telechelic α,ω-
dihydro(polydimethylsiloxane) was synthesized by cationic ring-opening polymerization of 
octamethylcyclotetrasiloxane (D4) in the presence of tetramethyldisiloxane. Reports of monodisperse 
PDMS in the literature are rare31 due to the low bond strength of the Si-O backbone repeat unit and 
the continual equilibrium state of the chains. This makes it difficult to use the controlled “living” 
polymerization techniques often used with carbon-based backbone polymers.30 Fortunately α,ω-
dihydro(polydimethylsiloxane) can be readily distilled under vacuum to remove lower MW linear and 
cyclic oligomers. The allyl-PEGs were reacted with the purified α,ω-dihydro(polydimethylsiloxane)s 
using traditional hydrosilylation conditions to generate ABA PDMS-PEGs with a range of MWs from 
1300 to 5200 Da and HLB factors from 5.9 to 16.6.  
When primary fibroblasts were treated with the oligomers, it was found that those with low MW (< 
3000, Fig. 4) or mid range hydrophilicity (HLB 7.5 to 13, Fig. 5) led to the most significant reduction 
in cell proliferation. In order to derive a single number that would be representative of each oligomer 
in terms of size and polarity as a function of proliferation we used the ratio of HLB on MW then 
multiplied this by 100 to get a range of values from 0.3-0.6 for our library. It was shown in Fig. 6 that 
as the value for 100HLB/MW increases, the fibroblast proliferation approached zero, revealing a 
relationship between the structure of PDMS-PEG oligomers and fibroblast proliferation. The plot 
suggests that zero proliferation will occur at 100HLB/MW of 0.65 to 0.9 (from extrapolation to the x-
axis), dependent on concentration. This hypothesis is supported by the previously studied rake 
system,12 which has a calculated value of 0.9 for 100HLB/MW and showed a down-regulation of 
fibroblast proliferation to 0.05 at a concentration of 0.10 wt%, consistent with the extrapolation of the 
results from the PEG-PDMS-PEG block copolymers shown in Fig. 6. 
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The present research focused on amphiphilic oligomers synthesized from PEG and PDMS linear 
structure combinations. However, there are other ABA copolymer combinations where links have 
been shown between copolymer structure and biological interactions. An alternative series of 
amphiphilic ABA block copolymers are Pluronics, consisting of ethylene oxide (EO) and propylene 
oxide (PO) repeating units (EOx–POy–EOx). These are extensively used with the medical industry due 
to their low toxicity.32 Surprisingly, they have also been shown to cause hypersensitivity in cells 
resulting in an increased cytotoxic response to antineoplastic agents.33 Batrakova et al.34-35 have 
investigated this hypersensitivity and correlated it to the number of EO and PO repeating units. 
Evaluating a library of Pluronics, where the copolymer MW ranged from 2000 to 15000 and HLB 
from 2 to 16, Batrakova et al.35 found that the different numbers of EO and PO units affected the P-
glycoprotein drug efflux and intracellular ATP synthesis, therefore altering cellular drug uptake. 
However, the investigated Pluronics were shown not to affect cell toxicity, unlike the PDMS–PEG 
oligomers studied here. Furthermore, the biological response was shown to occur over a range of HLB 
(2.8 to 10 on the scale defined by equation 1) and MW (2855 to 4968 Da). However, if these numbers 
are expressed as 100HLB/MW they fall within the range of 0.10 to 0.22, which are indicative of more 
hydrophobic cell interactions and much lower than the values of 0.5 to 0.6 found here for the  
PDMS-PEG oligomers resulting in down-regulation of fibroblasts. 
Other block copolymers have also been studied in cell culture. Zastre et al.13 investigated the 
suitability of methoxypolyethylene glycol–b–poly(caprolactone) (mPEG–PCL) for drug delivery via 
cellular accumulation experiments using the model drug rhodamine-123. In addition to measuring 
accumulation, they also measured toxicity of mPEG–PCL on exposure to caco-2 cells, where they 
observed a link between copolymer structure and cellular toxicity. In our study, the proliferation of 
dermal fibroblasts when exposed to 1 % wt/v of PEG4–PDMS10.5–PEG4 was reduced by 90%, whereas 
decreasing the exposure concentration to 0.1 % wt/v resulted in no reduction in cell proliferation. A 
mPEG–PCL copolymer of comparable MW13 also showed minimal effect with respect to cell toxicity, 
except at the highest concentration of 2 % wt/v. This is similar to the result for PEG4–PDMS10.5–PEG4 
at 1 % wt/v. Additionally, a study conducted by Allen et al.36 investigated block copolymers formed 
from polycaprolactone–b–poly(ethylene oxide) (PCL-b-PEO) and compared copolymer molecular 
weight and cellular viability. They demonstrated the low MW copolymer (PCL14-b-PEO44) decreased 
cell viability, whereas the higher MW copolymer (PCL20-b-PEO44) did not, which is similar to our 
observations. 
PDMS-PEG copolymers are known to have unusual water dispersion behavior8 which was evident in 
the microscopy images taken when investigating changes in fibroblast morphology. In most cases 
cloudiness and phase separation of the oligomers in the medium was present (Fig. 3). Oligomer 
critical aggregation concentration (CAC) (Fig. 2) represents the quantitative evaluation of this 
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solution property and represents the concentration at which the oligomers aggregate together forming 
assemblies such as vesicles. This differs from the critical micelle concentration at which the oligomers 
above this concentration form micelles.  CAC values could only be determined for the more 
hydrophilic oligomers synthesized from PEG16 or PEG44. While CAC values for oligomers with PEG4 
and PEG8 could not be determined due to considerable phase separation, it is estimated from Fig. 2 
that the aggregation begins above approximately 0.01 % wt/v meaning all the proliferation data of 
these oligomers contained multimeric structures. Comparing the fibroblast proliferation data (Table 
2) with the CAC data we see that there is no clear distinction between those oligomers with and 
without measureable CAC and the cell proliferation. We can therefore conclude that CAC alone does 
not offer any predictive insight into what effect the oligomer will have on fibroblast proliferation. 
The fate and mechanism of the PDMS–PEGs in the cell culture experiments was of great interest. 
However, tracking the copolymers using spectroscopy or labeling techniques proved problematic due 
to the surface spreading nature of the materials, making fixation elusive. Similarly, encapsulation and 
tracking of a fluorescent dye within PDMS–PEG micelles was unsuccessful due to the lack of micelle 
stability and resulted in continual bleed of the dye leading to non-specific staining. Covalent tethering 
of a fluorescent dye was also considered, however, the relatively low molecular weight of the PDMS-
PEGs meant the dye would have a non-negligible contribution to the overall structure and hence skew 
the results. We can assume, however, that the copolymers do penetrate or interact with the cell 
membrane based on their lipid-like properties. Kempe et al.37 have shown the presence of 
fluorescently labeled amphiphilic copoly(2-oxazoline) within the cell cytosol. Additionally, 
Batrokova et al.35 demonstrated intracellular localization of fluorescently labeled Pluronics and stated 
that while further investigation into the mechanism is required, Pluronics with a higher lipophilic 
content may enter cells through endocytosis.  
In summary, the results presented show the complexities that arise when examining the change in 
linear ABA PDMS–PEG block oligomers and the effect on dermal fibroblast proliferation. The 
number of both PDMS and PEG repeating units were altered; as a result, a series of oligomers were 
obtained varying in molecular weight and hydrophilic-lipophilic balance. Assessment of oligomer 
molecular weight and hydrophilic-lipophilic balance found that both properties affected the resulting 
proliferation. The major finding regarding oligomer property and proliferation is that as the variable 
100HLB/MW increased the fibroblast proliferation approached zero and can be used as a predictor of 
cell proliferation. These results, in addition to previous studies conducted, show the potential for 
amphiphilic siloxane oligomers as a therapeutic agent for hypertrophic scar remediation and as a 
therapy for reducing fibroblast proliferation. Further research is underway investigating the 
mechanistic actions the synthesized siloxane oligomers have on not only dermal fibroblasts, but also 
epidermal keratinocytes.  
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Captions 
Scheme 1: Synthesis of PEG-PDMS-PEG block copolymers via Pt-catalyzed hydrosilylation. 
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Table 1. Identification and properties of synthesized ABA block oligomers including the number of 
PDMS and PEG repeating units, oligomer molecular weight, HLB and critical aggregation 
concentration (% wt/v). Schematic structures for each oligomer represent the ABA block structure of 
the PEG–PDMS–PEG oligomers, size of PDMS and PEG shapes depict the differences between the 
synthesized oligomers; note size and volume are not to scale. 
 
Table 1. 
Oligomer ID PDMS-PEG schematic structure (PDMS = box, PEG = line) 
PDMS 
Units 
PEG 
units MW (Da) HLB 
CAC 
(% 
wt/v) 
PEG4-PDMS10.5-PEG4  10.5 4 1335 7.5 - 
PEG4-PDMS15.2-PEG4 
 
15.2 4 1684 5.9 - 
PEG8-PDMS10.5-PEG8  10.5 8 1687 10.1 - 
PEG16-PDMS10.5-PEG16 
 
10.5 16 2392 13.0 0.020 
PEG16-PDMS15.2-PEG16 15.2 16 2741 11.4 0.022 
PEG44-PDMS10.5-PEG44 10.5 44 4859 16.6 0.149 
PEG44-PDMS15.2-PEG44 15.2 44 5208 15.5 0.060 
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Table 2: Fibroblast proliferation following 48 hours exposure to each of the examined oligomers at 
various concentrations. Results presented as the number of fibroblasts remaining, determined via 
Cyquant assay, exposed to the oligomer as a ratio of fibroblasts remaining after exposure to the 
control. Data represents average ± SEM, * denotes statistically significant with respect to the control 
(p < 0.05) 
 
Table 2 
 1 % wt/v 0.10 % wt/v 0.01 % wt/v 0.001 % wt/v 
PEG4-PDMS10.5-PEG4 0.10 ± 0.01* 1.01 ± 0.05 1.04 ± 0.06 1.00 ± 0.04 
PEG4-PDMS15.2-PEG4 0.77 ± 0.03* 1.13 ± 0.04* 1.07 ± 0.07 0.99 ± 0.04 
PEG8-PDMS10.5-PEG8 0.33 ± 0.01* 0.56 ± 0.04* 0.56 ± 0.04* 0.74 ± 0.05* 
PEG16-PDMS10.5-PEG16 0.11 ± 0.02 * 0.14 ± 0.04 * 0.85 ± 0.05 0.93 ± 0.05 
PEG16-PDMS15.2-PEG16 0.59 ± 0.04* 0.78 ± 0.03 * 1.04 ± 0.07 1.06 ± 0.08 
PEG44-PDMS10.5-PEG44 0.93 ± 0.05 0.98 ± 0.06 0.99 ± 0.05 1.00 ± 0.07 
PEG44-PDMS15.2-PEG44 0.91 ± 0.04 1.05 ± 0.04 1.04 ± 0.06 1.00 ± 0.04 
 
 
 
Figure 1. Structures of the silicone oligomers. A) The low molecular weight fraction from a 
commercially available PDMS–PEG rake copolymer, containing a dimethyl siloxane backbone 7 
units long with 2 methoxy PEG 350 as pendant groups. B) ABA structure of the synthesized 
oligomers where n represents the number of dimethyl siloxane repeating units and m the number of 
PEG repeating units. 
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Figure 2: Assessment of oligomer critical aggregation concentration, representing oligomer surface 
tension (mN/m) as a function of oligomer concentration (% wt/v).  
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Figure 3. Representative images of dermal fibroblasts displaying morphology after 48 hours exposure 
of 1 % wt/v of the test oligomers A) PEG4–PDMS15.2–PEG4, B) PEG4–PDMS10.5–PEG4, C) PEG8–
PDMS10.5–PEG8, D) PEG16–PDMS15.2–PEG16, E1) PEG16–PDMS10.5–PEG16 E2)PEG16–PDMS10.5–
PEG16 (test solution, containing oligomer, has been removed to aid observation of fibroblast 
morphology), F) PEG44–PDMS15.2–PEG44, G) PEG44–PDMS10.5–PEG44, and H) control dermal 
fibroblasts. Images are shown in order of increasing HLB, from the lowest A) PEG4–PDMS15.2–PEG4 
(HLB = 5.9) to highest F) PEG44–PDMS10.5–PEG44 (HLB = 16.6). Scale bar represents 100μm. 
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Figure 4 (top): The change in oligomer molecular weight and the effect on fibroblast proliferation. 
Results show, in general, fibroblast exposure to oligomers of lower molecular weight significantly 
reduce fibroblast proliferation at concentrations of 0.01 and 1.0 % wt/v. Results presented show 
oligomer exposure concentrations from 0.001 to 1 % wt/v. Figure 5 (bottom): The change in 
oligomer hydrophilicity and the effect on fibroblast proliferation. Results show, in general, fibroblast 
exposure to oligomers of intermediate HLB factor significantly reduce fibroblast proliferation at 
concentrations of 0.01 and 1.0 % wt/v. Results presented show oligomer exposure concentrations 
from 0.001 to 1 % wt/v.  
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Figure 6: Representation of the relationship between fibroblast proliferation and 100HLB/MW, for an 
exposure concentration of 1 and 0.1 % wt/v of the PDMS-PEG oligomers. Results reveal as 
100HLB/MW increases fibroblast proliferation approaches zero, with intercepts at this point being 
0.65 and 0.9 for concentrations of 1.0 and 0.1 % wt/v, respectively. 
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Synthesis of discrete allyl-functional polyethylene glycol and hydrophilization of 
dihydro(polydimethylsiloxane) 
 
Experimental 
Materials. All solvents were of AR grade unless otherwise stated. Allyl bromide (99 %), 
diethylene glycol (99 %),  diethylene glycol methyl ether (99 %), tetraethylene glycol (99 %), 
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polyethylene glycol 750 methyl ether, polyethylene glycol 2000 methyl ether, p-
toluenesulfonyl chloride (98 %), octamethylcyclotetrasiloxane (99 %), tetramethyldisiloxane 
(97 %), trifluoromethanesulfonic acid (99 %), hexachloroplatinic acid hexahydrate (≥37.5 % 
Pt), sodium (99.9 %), sodium hydride (60 % dispersion in mineral oil), potassium tert-
butoxide (97 %) and 1,6-diphenyl-1,3,5-hexatriene were purchased from Sigma-Aldrich. 
Analytical thin layer chromatography (TLC) was performed on Merck Silica Gel F254 TLC 
plates and visualized using a potassium permanganate dip. Preparative column 
chromatography was performed using Merck Silica Gel 60 (mesh 230-400).  
 
Characterization. Nuclear magnetic resonance (NMR) spectra obtained on a Bruker Avance 
400 MHz spectrometer (1H 400 MHz, 13C 100 MHz). Electrospray ionization (ESI) mass 
spectra were recorded at the Australian National University using a Bruker Apex 3 Fourier 
transform ion cyclotron resonance mass spectrometer with a 4.7 T magnet.  Gel permeation 
chromatography (GPC) was performed at CSIRO on a system comprising a Waters liquid 
chromatograph equipped with a differential refractometer and 3 × mixed C and 1 mixed E 
PLgel columns (each 300 mm × 7.5 mm) from Polymer Laboratories.  The eluent was 
tetrahydrofuran (THF) at 22 °C (flow rate: 1 mL min-1). Number (Mn) and weight-average 
(Mw) molecular weights were evaluated using Waters Millennium software. The GPC 
columns were calibrated with narrow polydispersity polystyrene standards (Polymer 
Laboratories) and molecular weights are reported as polystyrene equivalents. A third order 
polynomial was used to fit the log M vs. time calibration curve, which was linear across the 
molecular weight range 2 × 102 – 2 × 106 g mol-1.  
 
Synthesis of allyl functional PEG 
Tetraethylene glycol allyl ether 
To tetraethylene glycol (51.4 mL, 58.2 g, 300 mmol, 4 equiv.) heated at 100 °C under argon was 
added Na (1.8 g, 75 mmol, 1 equiv.) in small portions. The reaction mixture was stirred at a constant 
temperature until all the Na had dissolved after which the hot glycolate was added dropwise via 
cannula to an ice cooled flask under argon containing allyl bromide (6.56 mL, 9.18 g, 75 mmol, 1 
equiv.). The resultant mixture was heated at 170 °C for 2 h under argon, cooled and filtered to give a 
brown viscous liquid. This crude mixture was subjected to column chromatography (SiO2, 20 % 
EtOH/80 % EtOAc) which gave tetraethylene glycol allyl ether (6.084 g, 26 mmol, 35 %) δH: (CDCl3) 
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3.25 (1H, br, OH), 3.54-3.70 (16H, m, OCH2CH2O), 3.98 (2H, d, J 5.9 Hz, =CHCH2O), 5.14 (1H, dd, 
J 1.1 and 10.0 Hz, HcisC=CHCH2O), 5.23 (1H, dd, J 1.1 and 17.0, HtransC=CHCH2O), 5.87 (1H, m, J 
5.9, 10.0 and 17.0, H2C=CHCH2O); δC: (CDCl3); 61.6, 70.1, 70.5, 70.5, 70.5, 72.2, 72.7, 117.3, 134.5. 
 
Tetraethylene glycol di(p-toluensulfonate) 
Tetraethylene glycol (86.3 mL, 97.12 g, 0.5 mol) and p-toluenesulfonyl chloride (194.5 g, 1.02 mol, 
2.04 equiv.) were dissolved in DCM (500 mL). The resultant solution was cooled to 0 °C and had 
KOH (225 g, 4 mol, 8 equiv.) added. The reaction mixture was then allowed to warm to RT and 
stirred for 16 h. After the reaction was complete the mixture was poured onto ice/water (500 mL) and 
extracted with DCM (3 × 250 mL). The organic fraction was washed with H2O (3 × 250 mL), after 
which the combined aqueous fractions were back extracted with DCM (2 × 250 mL. The combined 
organics were dried (Na2SO4) and the solvent removed under reduced pressure to give tetraethylene 
glycol p-ditoluenesulfonate (226.51 g, 0.45 mol, 90 %) as a colourless, viscous liquid. δH: (CDCl3) 
2.43 (6H, s, CH3), 3.55 (8H, s, OCH2CH2O), 3.67 (4H, t, J 4.1 Hz, OCH2CH2O), 4.14 (4H, t, J 4.1 Hz, 
OCH2CH2OS), 7.33 (4H, d, J 7.6 Hz, ArCH), 7.78 (4H, d, J 7.6 Hz, ArCH); δC: (CDCl3); 21.6, 68.6, 
69.3, 70.4, 70.6, 127.9, 129.8, 132.9, 144.8. 
 
p-Toluenesulfonyl octaethylene glycol allyl ether 
To a solution of tetraethylene glycol allyl ether (33.6 g, 0.143 mol) in dry THF (300 mL) was added 
potassium tert-butoxide (16.2 g, 0.144 mol, 1 equiv.). The resultant reaction mixture stirred under 
argon at RT for 2 h after which the solution was cooled to 0 °C. A solution of tetraethylene glycol 
di(p-toluensulfonate) (144.2 g, 0.287 mol, 2 equiv.) in dry THF 300 mL was added dropwise to the 
reaction mixture, which was then stirred under argon at 60 °C for 16 h. The mixture was cooled, 
filtered and the solid fraction was washed with THF and EtOAc. The solvent was removed under 
reduced pressure and the residue obtained was purified by column chromatography (SiO2: 10 % 
EtOH/90 % EtOAc) to give p-toluenesulfonyl octaethylene glycol allyl ether (26.8 g, 0.047 mol, 33 
%) as a viscous, colourless liquid. δH: (CDCl3) 2.45 (3H, s, CH3), 3.56-3.71 (30H, m, OCH2CH2O), 
4.02 (2H, d, J 5.9 Hz, =CHCH2O), 4.16 (2H, t, J 4.7 Hz, OCH2CH2OS), 5.18 (1H, dd, J 1.4 and 10.6 
Hz, HcisC=CHCH2O), 5.27 (1H, dd, J 1.4 and 17.0, HtransC=CHCH2O), 5.92 (1H, m,  J 5.9, 10.6 and 
17.0, H2C=CHCH2O), 7.35 (2H, d, J 8.2 Hz, ArCH), 7.80 (2H, d, J 8.2 Hz, ArCH); δC: (CDCl3); 21.6, 
68.7, 69.2, 69.4, 70.5, 70.5, 70.6, 70.6, 70.6, 70.6, 70.7, 72.2, 117.1, 128.0, 129.8, 133.0, 134.8, 144.8. 
+ESI MS found (M+H)+ 565.2680 (0.5 ppm from calc. mass of C26H45O11S+ 565.2683). 
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Octaethylene glycol allyl methyl ether 
p-Toluenesulfonyl octaethylene glycol allyl ether (514 mg, 0.91 mmol) was dissolved in MeOH (5 
mL) and aq. NaOH (5mL, 5 M). The reaction mixture was heated under reflux for 2 h, after which 
HCl (2M) was added (pH ~1). The resulting solution was extracted with DCM (3 × 25 mL) and the 
combined organics washed with H2O (2 × 25 mL). The aqueous fractions were back extracted with 
DCM (2 × 25 mL) and the combined DCM layers were washed with brine (2 × 25 mL), dried 
(Na2SO4) and the solvent was removed under reduced pressure. The isolated residue was purified by 
column chromatography (SiO2: 20 % EtOH/80 % EtOAc) giving octaethylene glycol allyl methyl 
ether (279 mg, 0.66 mmol, 73 %) as a colourless, viscous liquid. δH: (CDCl3) 3.37 (3H, s, OCH3), 
3.51-3.68 (32H, m, OCH2CH2O), 4.01 (2H, d, J 5.6 Hz, =CHCH2O), 5.16 (1H, dd, J 1.5 and 10.3 Hz, 
HcisC=CHCH2O), 5.26 (1H, dd, J 1.5 and 17.0, HtransC=CHCH2O), 5.90 (1H, m,  J 5.6, 10.3 and 17.0, 
H2C=CHCH2O); δC: (CDCl3); 59.0, 69.4, 70.5, 70.6, 70.6, 70.6, 70.6, 71.9, 72.2, 117.1, 134.8. +ESI 
MS found (M+H)+ 425.2751 (0.0 ppm from calc. mass of C20H41O9+ 425.2751). 
 
Polyethylene glycol 750 allyl methyl ether 
To a solution of poly(ethyleneglycol) 750 methyl ether (11.03 g, 14.7 mmol,) in dry THF (40 mL) 
was added a suspension of NaH (0.76 g, 80 % in mineral oil) in THF (5 mL). The reaction was stirred 
for 2 h at RT after which allyl bromide (3.73 mL, 5.22 g, 43.5 mmol, 3 equiv.) was added dropwise. 
The resultant reaction mixture was stirred at RT for 24 h, diluted with EtOAc and filtered, and the 
solvent removed under reduced pressure to give a colourless liquid that solidified upon standing (11.5 
g, 99 %, 86 % pure by 1H NMR). The product was used without further purification. δH: (CDCl3) 3.35 
(3H, s, OCH3), 3.48-3.68 (~64H, m, OCH2CH2O), 3.99 (2H, d, J 5.6 Hz, =CHCH2O), 5.14 (1H, dd, J 
1.3 and 10.4 Hz, HcisC=CHCH2O), 5.24 (1H, dd, J 1.3 and 17.2, HtransC=CHCH2O), 5.88 (1H, m, J 
5.6, 10.4 and 17.2, H2C=CHCH2O); δC: (CDCl3); 59.0, 63.4, 70.5, 70.5, 70.6, 71.9, 72.2, 117.1, 134.7. 
 
Polyethylene glycol 2000 allyl methyl ether  
To a solution of poly(ethyleneglycol) 2000 methyl ether (29.4 g, 14.7 mmol,) in dry THF (70 mL) 
was added a suspension of NaH (0.76 g, 80 % in mineral oil) in THF (5 mL). The reaction was stirred 
for 2 h at RT after which allyl bromide (3.73 mL, 5.22 g, 43.5 mmol, 3 equiv.) was added dropwise. 
The resultant reaction mixture was stirred at RT for 24 h, diluted with EtOAc and filtered, and the 
solvent removed under reduced pressure to give a colourless liquid that solidified upon standing (29.9 
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g, 99 %, 92 % pure by 1H NMR). The product was used without further purification. δH: (CDCl3) 3.35 
(3H, s, OCH3), 3.48-3.68 (~180H, m, OCH2CH2O), 3.99 (2H, d, J 5.6 Hz, =CHCH2O), 5.14 (1H, dd, J 
1.3 and 10.4 Hz, HcisC=CHCH2O), 5.24 (1H, dd, J 1.3 and 17.2, HtransC=CHCH2O), 5.88 (1H, m, J 
5.6, 10.4 and 17.2, H2C=CHCH2O); δC: (CDCl3); 59.0, 63.4, 70.5, 70.6, 71.9, 72.2, 117.1, 134.7. 
 
Synthesis of hydrosilane end functional poly(dimethylsiloxane) 
α,ω-Dihydro(polydimethylsiloxane) n = 10.5 
To a mixture of octamethylcyclotetrasiloxane (D4, 30 g, 31.41 mL, 101 mmol) and 
tetramethyldisiloxane (TMDS, 13.8 g, 18.16 mL, 102 mmol) trifluoromethanesulfonic acid (300 μL, 
509 mg, 3.4 mmol, 3.4 mol%) was added and the reaction mixture was stirred at 100 °C for 5 h, after 
which the reaction was quenched on NaHCO3 (2 g) with stirring. The reaction mixture was diluted 
with Et2O filtered and the solvent removed under reduced pressure. The resulting low molecular 
weight, residual TDMS and unwanted cyclics were removed by kugelrohr distillation to give linear 
dihydro-PDMS as a colourless, viscous liquid (25.4 g, Mn = 840, Mw/Mn = 1.7). 1H NMR: δH: 
(CDCl3) 0.04-0.12 (~60H, m, SiCH3), 0.18-0.20 (~12H, m, HSiCH3), 4.69-4.74 (2H, m, SiH). 
 
α,ω-Dihydro(polydimethylsiloxane) n = 15.2 
To a mixture of octamethylcyclotetrasiloxane (D4, 30 g, 31.41 mL, 101 mmol) and 
tetramethyldisiloxane (TMDS, 6.9 g, 9.08 mL, 51 mmol) trifluoromethanesulfonic acid (300 μL, 509 
mg, 3.4 mmol, 3.4 mol%) was added and the reaction mixture was stirred at 100 °C for 5 h, after 
which the reaction was quenched on NaHCO3 (2 g) with stirring. The reaction mixture was diluted 
with Et2O filtered and the solvent removed under reduced pressure. The resulting low molecular 
weight, residual TDMS and unwanted cyclics were removed by kugelrohr distillation to give the 
linear PDMS 14 as a colourless, viscous liquid (19.7 g, Mn = 1190, Mw/Mn = 2.1) 1H NMR: δH: 
(CDCl3) 0.04-0.12 (~84H, m, SiCH3), 0.18-0.20 (~12H, m, HSiCH3), 4.69-4.74 (2H, m, SiH). 
 
Synthesis of poly(ethyleneglycol)-poly(dimethylsiloxane) ABA block copolymers 
dPEG8-PDMS10.5-dPEG8  
Octaethyleneglycol allyl methyl ether (3.35 g, 7.9 mmol, ~2.2 equiv.) and α,ω–
dihydro(polydimethylsiloxane) (3.05 g, Mn = 840, ~3.58 mmol) were dissolved in toluene (10 mL) 
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and heated to 90°C under argon in a Schlenk vessel. Speier’s catalyst (70 µL, 2 % w/v H2(PtCl6).6H2O 
in i–PrOH) was added and the resulting solution was heated at 130 °C in a sealed Schlenk tube for 16 
h after which activated charcoal was added to the solution and stirred for 16 h. The product was 
filtered and solvent removed. The reaction product was purified by an n–pentane and methanol wash 
to give the dPEG8-PDMS10.5-dPEG8 copolymer as a colourless, viscous liquid (4.83 g, GPC (THF): 
Mn = 1760, Mw/Mn = 1.10). 1H NMR: δH: (CDCl3) -0.01-0.04 (~72H, m, SiCH3), 0.48 (4H, m, CH2Si), 
1.56 (4H, m, CH2CH2Si), 3.33 (6H, s, OCH3), 3.36-3.66 (68H, m, OCH2CH2O). 
 
PEG16-PDMS10.5-PEG16  
Polyethylene glycol 750 allyl methyl ether (1.35 g, 1.71 mmol, ~2.2 equiv.) and α,ω–
dihydro(polydimethylsiloxane) (0.66 g, Mn = 850, ~0.78 mmol) were dissolved in toluene (2.2 mL) 
and heated to 90°C under argon in a Schlenk vessel. Speier’s catalyst (30 µL, 2 % w/v H2(PtCl6).6H2O 
in i–PrOH) was added and the resulting solution was heated at 130 °C in a sealed Schlenk tube for 16 
h after which activated charcoal was added to the solution and stirred for 16 h. The product was 
filtered and solvent removed. The reaction product was purified by an n–pentane and methanol wash 
to give  the PEG16-PDMS10.5-PEG16 copolymer as a colourless, viscous liquid (1.81 g, GPC (THF): 
Mn = 3000, Mw/Mn = 1.10; 1H NMR: δH: (CDCl3) 0.01-0.09 (~72H, m, SiCH3), 0.50 (4H, m, CH2Si), 
1.60 (4H, m, CH2CH2Si), 3.37 (6H, s, OCH3), 3.36-3.66 (~132H, m, OCH2CH2O). (~8 % PEG 
impurity from NMR) 
 
PEG44-PDMS10.5-PEG44  
Polyethylene glycol 2000 allyl methyl ether (1.68 g, 0.83 mmol, ~2.2 equiv) and α,ω–
dihydro(polydimethylsiloxane) (0.32 g, Mn = 850, ~0.38 mmol) were dissolved in toluene (2.2 mL) 
and heated to 90°C under argon in a Schlenk vessel. Speier’s catalyst (30 µL, 2 % w/v H2(PtCl6).6H2O 
in i–PrOH) was added and the resulting solution was heated at 130 °C in a sealed Schlenk tube for 16 
h after which activated charcoal was added to the solution and stirred for 16 h. The product was 
filtered and solvent removed. The reaction product was purified by an n–pentane and methanol wash 
to give the PEG44-PDMS10.5-PEG44 copolymer as a colourless solid (1.72 g, GPC (THF): Mn = 7820, 
Mw/Mn = 1.02; 1H NMR: δH: (CDCl3) 0.00-0.13 (~72H, m, SiCH3), 0.50 (4H, m, CH2Si), 1.60 (4H, m, 
CH2CH2Si), 3.37 (6H, s, OCH3), 3.39-3.81 (~364H, m, OCH2CH2O). (~10 % PEG impurity from 
NMR) 
 
